法国乳企启动奶粉召回牵动产业链，国内ARA龙头嘉必优面临大考

Core Viewpoint - The recent large-scale recall of infant formula by Lactalis, following a similar action by Nestlé, has raised significant concerns for domestic suppliers, particularly for the largest ARA supplier in China, Jia Bi You, which is now under scrutiny due to potential links to these safety incidents [1][3]. Group 1: Recall Events - Lactalis announced a recall of multiple batches of infant formula in 18 countries due to potential contamination with Bacillus cereus toxins, which can cause diarrhea and vomiting [1]. - Nestlé previously recalled a batch of infant formula in several European countries due to quality issues with an ARA oil ingredient supplied by a vendor [1]. Group 2: Impact on Jia Bi You - Jia Bi You has received attention as a key ARA supplier for major infant formula brands, including Nestlé, and has been urged by the Shanghai Stock Exchange to fulfill its information disclosure obligations in light of the recalls [1][3]. - The company reported a revenue of 560 million yuan in 2024, with over 70% of this revenue coming from its ARA business, highlighting its critical role in the company's operations [3]. Group 3: International Expansion and Financial Outlook - Jia Bi You is in a crucial phase of international expansion, with overseas revenue reaching 210 million yuan in 2024, accounting for 38% of total revenue and showing a year-on-year growth of 26.39% [3]. - The gross profit margin for international business exceeds 51%, indicating a growing profitability advantage in its international operations [3]. Group 4: Future Challenges - The outcome of the product testing will be a pivotal moment for Jia Bi You's short-term development; a favorable result could help the company return to normal operations, while any issues could lead to significant challenges in rectifying trust and compliance [3][4]. - Analysts predict that the current crisis may lead to a temporary cessation of product use by both domestic and international companies, posing immediate financial risks, including potential declines in stock price and performance [4].